Novartis has entered a new partnership with Monte Rosa Therapeutics, securing an exclusive license to a novel molecular glue degrader drug candidate and options on two additional preclinical programs targeting immune-mediated diseases. The deal provides $120 million upfront and could reach $5.7 billion with milestones and royalties. Building on their ongoing collaboration, this agreement aims to accelerate the development of targeted protein degradation therapies with potential to address challenging immune disorders. Monte Rosa’s QuEEN platform combines AI-driven chemistry and proteomics to advance selective molecular glues, reflecting Novartis’ commitment to innovative drug modalities.